Cargando…
Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
Interferon Beta-1a (IFN-β1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2. COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of...
Autores principales: | Baghaei, Parvaneh, Dastan, Farzaneh, Marjani, Majid, Moniri, Afshin, Abtahian, Zahra, Ghadimi, Somayeh, Valizadeh, Melika, Heshmatnia, Jalal, Sadat Mirenayat, Maryam, Abedini, Atefeh, Kiani, Arda, Eslaminejad, Alireza, MohammadReza Hashemian, Seyed, Jamaati, Hamidreza, Zali, Alireza, Akbar Velayati, Ali, Tabarsi, Payam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762801/ https://www.ncbi.nlm.nih.gov/pubmed/33412395 http://dx.doi.org/10.1016/j.intimp.2020.107329 |
Ejemplares similares
-
Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran
por: Baghaei, Parvaneh, et al.
Publicado: (2020) -
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2020) -
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
por: Tabarsi, Payam, et al.
Publicado: (2021) -
NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals
por: Marjani, Majid, et al.
Publicado: (2020) -
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)